

# Vitaly Omelyanovsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938047/publications.pdf>

Version: 2024-02-01

54  
papers

108  
citations

1478505

6  
h-index

1372567

10  
g-index

56  
all docs

56  
docs citations

56  
times ranked

106  
citing authors



| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Parameters for evaluating the main indicators of coloproctological care in the adult population in the subjects of the far Eastern Federal District in 2016–2018. <i>Farmakoekonomika</i> , 2020, 13, 240-250.   | 1.2 | 1         |
| 20 | Regulatory framework of the oncological medical care provision. <i>Farmakoekonomika</i> , 2020, 13, 304-315.   | 1.2 | 3         |
| 21 | The review of the foreign experience on the financing of innovative medical technologies. <i>Farmakoekonomika</i> , 2020, 13, 316-323.   | 1.2 | 1         |
| 22 | Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making. <i>Farmakoekonomika</i> , 2020, 13, 262-269.   | 1.2 | 1         |
| 23 | Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense. <i>Farmakoekonomika</i> , 2019, 11, 81-91. | 1.2 | 0         |
| 24 | International experience in determining the cost-effectiveness thresholds. <i>Farmakoekonomika</i> , 2019, 11, 73-80.  | 1.2 | 1         |
| 25 | Organizational structure and funding of health technology assessment agencies around the world. <i>Farmakoekonomika</i> , 2019, 12, 146-154.   | 1.2 | 1         |
| 26 | Health technology assessment and reimbursement of pharmaceuticals in Italy. <i>Farmakoekonomika</i> , 2019, 12, 156-164.   | 1.2 | 1         |
| 27 | Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019. <i>Farmakoekonomika</i> , 2019, 12, 169-177.  | 1.2 | 0         |
| 28 | Diabetes mellitus as an economic problem in Russian Federation. <i>Diabetes Mellitus</i> , 2016, 19, 30-43.  | 1.9 | 17        |
| 29 | Direct Costs of Unintended Pregnancy in the Russian Federation. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 61-68.   | 2.1 | 4         |
| 30 | The Cost of Melanoma and Kidney, Prostate, and Ovarian Cancers in Russia. <i>Value in Health Regional Issues</i> , 2014, 4, 58-65.   | 1.2 | 4         |
| 31 | Mcdca Approach To Ranking Rare Diseases In Russia: Preliminary Results. <i>Value in Health</i> , 2014, 17, A539.   | 0.3 | 9         |
| 32 | Efficiency Of Rehabilitation Programs For Patients After Traumatic Brain Injury And Acute Cerebrovascular Accident (Stroke) In Russia. <i>Value in Health</i> , 2014, 17, A490.                                  | 0.3 | 0         |
| 33 | Fixed Dose Combinations of Nucleoside Reverse Transcriptase Inhibitor for Naïve Patient with Hiv Infection in Russia: Cost Comparison Analysis. <i>Value in Health</i> , 2014, 17, A669.                         | 0.3 | 0         |
| 34 | Cost-Effectiveness Analysis Of Antiviral Pharmacotherapies For Treatment Of Chronic Hepatitis C Virus Infection In Russia. <i>Value in Health</i> , 2014, 17, A366-A367.   | 0.3 | 0         |
| 35 | Estimating the Costs of Drug Supply for Rare Diseases Patients In Russia. <i>Value in Health</i> , 2014, 17, A525.   | 0.3 | 0         |
| 36 | Potential Economic Impact of Using Sugammadex for the Routine Reversal of Neuromuscular Blockade in Russian Health Care Setting. <i>Value in Health</i> , 2013, 16, A558-A559.                                   | 0.3 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Cost-Minimization Analysis of Maraviroc Versus Darunavir Raltegravir and Enfuvirtide for CCR5-Tropic Treatment-Experienced Patients with HIV Infection in Russia. Value in Health, 2013, 16, A358-A359.     | 0.3 | 0         |
| 38 | Pharmacoeconomic Evaluation of the Fixed-Dose Combination of Abacavir/Lamivudine in the Antiretroviral Therapy of Naïve HIV Infected Patients in Russia. Value in Health, 2013, 16, A345-A346.              | 0.3 | 0         |
| 39 | Costs Associated with Cold Chain Used to Store and Transport Thermally Unstable Antiretroviral Drugs. Value in Health, 2013, 16, A360.  | 0.3 | 0         |
| 40 | Comparative Economic Analysis of Retreatment Strategies for HCV Genotype 1 Patients in Russia. Value in Health, 2013, 16, A498.   | 0.3 | 0         |
| 41 | The Cost of Specialized Hospital Care for Patients with Diabetic Foot Ulcers in Russia. Value in Health, 2013, 16, A444.  | 0.3 | 0         |
| 42 | PRS23 Pharmacoeconomic Analysis of Roflumilast for Treatment of Adult Patients With Severe-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD). Value in Health, 2012, 15, A563.                    | 0.3 | 0         |
| 43 | PIH12 Burden of Early-Onset Neonatal Sepsis in the Russian Federation. Value in Health, 2012, 15, A538.   | 0.3 | 0         |
| 44 | PCN49 Economic Burden of Melanoma in Russia. Value in Health, 2012, 15, A417.   | 0.3 | 1         |
| 45 | PCN57 Economic Burden of Prostate Cancer in Russia. Value in Health, 2012, 15, A419.  | 0.3 | 0         |
| 46 | PMS16 Economic Burden of Juvenile Idiopathic Arthritis in Russia. Value in Health, 2012, 15, A442.  | 0.3 | 0         |
| 47 | PUK17 Cost-Minimization Analysis of Pazopanib Versus Sunitinib, Sorafenib and Bevacizumab+ Interferon $\alpha_2$ for Patients With Metastatic Renal Cell Carcinoma. Value in Health, 2012, 15, A458.        | 0.3 | 0         |
| 48 | PCN97 Pharmacoeconomic Analysis of the Prostate Cancer Therapy with Gonadotropin-Releasing Hormone Analogues: Leuprorelin, Goserelin, Triptorelin. Value in Health, 2012, 15, A426-A427.                    | 0.3 | 0         |
| 49 | PRS42 Pharmacoeconomic Analysis of Methylprednisolone Aceponate for Treatment of Atopic Dermatitis and Eczema. Value in Health, 2011, 14, A495.   | 0.3 | 1         |
| 50 | PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia. Value in Health, 2011, 14, A277-A278.   | 0.3 | 0         |
| 51 | PCV17 Cost-Effectiveness Analysis of Bosentan and Sildenafil Compared with Standard therapy in Treatment of Primary Pulmonary Arterial Hypertension in Russian Federation. Value in Health, 2011, 14, A367. | 0.3 | 0         |
| 52 | PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis. Value in Health, 2011, 14, A506.  | 0.3 | 0         |
| 53 | PCN53 ANALYSIS OF SOCIOECONOMIC BUREDN OF HEPATOCELLULAR CARCINOMA IN RUSSIA. Value in Health, 2010, 13, A260-A261.   | 0.3 | 0         |
| 54 | PRS21 BURDEN OF BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN RUSSIA. Value in Health, 2010, 13, A322.  | 0.3 | 0         |